B. Metzler seel. Sohn & Co. AG Increases Stock Position in Ralliant Corporation $RAL

Key Points

• Institutional interest increased: B. Metzler seel. Sohn & Co. AG boosted its Ralliant position by 231.8% to 23,944 shares, while BlackRock, Viking Global, and State Street initiated new stakes during the second quarter.
• Analyst sentiment remains positive overall: Ralliant has a “Moderate Buy” consensus rating and an average price target of $75.70, despite some downgrades and a “sell” rating from Weiss Ratings.
• Ralliant exceeded quarterly earnings expectations: The company reported $0.68 in EPS versus the $0.63 consensus estimate, issued fiscal 2026 EPS guidance of $2.76–$2.90, and declared a quarterly dividend of $0.05 per share.

B. Metzler seel. Sohn & Co. AG lifted its position in shares of Ralliant Corporation (NYSE:RAL - Free Report) by 231.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 23,944 shares of the company's stock after buying an additional 16,727 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in Ralliant were worth $1,763,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. BlackRock Inc. purchased a new stake in shares of Ralliant during the 2nd quarter worth about $1,039,481,000. Dodge & Cox increased its position in shares of Ralliant by 13.3% in the fourth quarter. Dodge & Cox now owns 12,214,679 shares of the company's stock worth $621,849,000 after acquiring an additional 1,434,376 shares in the last quarter. Viking Global Investors LP acquired a new stake in shares of Ralliant in the second quarter worth $257,200,000. Millennium Management LLC raised its stake in shares of Ralliant by 172.4% in the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company's stock valued at $253,175,000 after acquiring an additional 3,147,660 shares during the period. Finally, State Street Corp purchased a new position in shares of Ralliant in the 2nd quarter valued at $213,096,000.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Royal Bank Of Canada upped their price target on shares of Ralliant from $71.00 to $73.00 and gave the stock a "sector perform" rating in a research report on Friday, July 31st. Vertical Research lowered Ralliant from a "buy" rating to a "hold" rating and set a $65.00 price objective on the stock. in a research report on Wednesday, May 27th. Zacks Research upgraded Ralliant from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, June 30th. TD Cowen upped their target price on Ralliant from $70.00 to $80.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. Finally, Weiss Ratings reaffirmed a "sell (d)" rating on shares of Ralliant in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Ralliant presently has an average rating of "Moderate Buy" and an average price target of $75.70.

Insiders Place Their Bets

In related news, CEO Tamara Newcombe sold 12,936 shares of Ralliant stock in a transaction on Friday, August 14th. The shares were sold at an average price of $71.79, for a total value of $928,675.44. Following the completion of the sale, the chief executive officer owned 251,967 shares in the company, valued at approximately $18,088,710.93. The trade was a 4.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karen Bick sold 6,062 shares of the company's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $72.00, for a total transaction of $436,464.00. Following the completion of the sale, the senior vice president directly owned 31,668 shares in the company, valued at $2,280,096. This represents a 16.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by insiders.

Ralliant Stock Up 1.1%

Shares of NYSE RAL opened at $63.46 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.00 and a current ratio of 1.52. Ralliant Corporation has a 1 year low of $37.27 and a 1 year high of $75.41. The stock's 50-day simple moving average is $67.52 and its 200-day simple moving average is $57.10. The firm has a market cap of $7.02 billion, a price-to-earnings ratio of -5.85, a PEG ratio of 2.36 and a beta of 1.54.

Ralliant (NYSE:RAL - Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported $0.68 EPS for the quarter, beating analysts' consensus estimates of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The firm had revenue of $567.80 million during the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, equities analysts anticipate that Ralliant Corporation will post 2.87 earnings per share for the current fiscal year.

Ralliant Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Stockholders of record on Tuesday, September 8th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Tuesday, September 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant's dividend payout ratio (DPR) is presently -1.84%.

About Ralliant

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

Want to see what other hedge funds are holding RAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ralliant Corporation (NYSE:RAL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source